These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7899894)

  • 1. Multiple myeloma: the National University Hospital (NUH) experience.
    Lim HL; Teo CP; Wong K; Kuperan P; Suri R; Tan YO; Kueh YK
    Singapore Med J; 1994 Aug; 35(4):371-3. PubMed ID: 7899894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
    Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T
    Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group.
    Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J
    Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group.
    Eur J Haematol; 1992 Jan; 48(1):37-40. PubMed ID: 1730278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of K18 (IgG-melphalan) for five cases of refractory multiple myeloma.
    Kanamaru R; Wakui A; Ishioka C; Okuno M; Konishi Y; Ishikawa A; Shibata H
    Sci Rep Res Inst Tohoku Univ Med; 1988 Dec; 35(1-4):35-40. PubMed ID: 3267125
    [No Abstract]   [Full Text] [Related]  

  • 8. [The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma].
    Li J; Zhao Y; Luo SK; Huang BH; Zhang GC; Peng AH; Zheng D; Su C; Xu DR; Tong XZ; Gu JL; Ding Y
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2140-3. PubMed ID: 19080477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria.
    Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Lal R; Singhal S; Mehta J; Horton C; Treleaven J
    Bone Marrow Transplant; 2001 Jul; 28(1):29-37. PubMed ID: 11498741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early response to therapy and survival in multiple myeloma.
    Schaar CG; Kluin-Nelemans JC; le Cessie S; Franck PF; te Marvelde MC; Wijermans PW
    Br J Haematol; 2004 Apr; 125(2):162-6. PubMed ID: 15059138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
    Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multiple myeloma].
    Kanoh T
    Rinsho Ketsueki; 1989 Aug; 30(8):1212-5. PubMed ID: 2601036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual serum proteins and acute phase reactants in monoclonal immunoglobulinopathies (a study in patients with IgA myeloma and light chain myeloma).
    Wiedermann D; Widermann B; Cídl K; Scudla V
    Neoplasma; 1979; 26(3):315-24. PubMed ID: 119165
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.
    Dimopoulos MA; Anagnostopoulos A; Terpos E; Repoussis P; Zomas A; Katodritou E; Kyrtsonis MC; Delibasi S; Vassou A; Pouli A; Zervas K; Anagnostopoulos N; Maniatis A;
    Haematologica; 2006 Feb; 91(2):252-4. PubMed ID: 16461313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of multiple myeloma: renal function in relation to its prognosis].
    Akashi M; Ohta M; Kitagawa S; Furukawa Y; Takeda K; Muroi K; Komatsu N; Ikeda K; Ohsaka A; Yoshida M
    Rinsho Ketsueki; 1988 Nov; 29(11):1991-7. PubMed ID: 3236408
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma in north east Scotland: a review of incidence and survival over three decades.
    Soutar RL; Dawson AA; Wilson BJ
    Health Bull (Edinb); 1996 May; 54(3):232-40. PubMed ID: 8707567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.